News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novo Nordisk (NVO) And Innovex (INVX) Enter Agreement To Deploy Sales Force To Sell Popular Menopause Treatments



10/19/2005 5:10:30 PM

PRINCETON, N.J. and RESEARCH TRIANGLE PARK, N.C., March 18 /PRNewswire- FirstCall/ -- Novo Nordisk Pharmaceuticals, Inc. and Innovex, the commercialization unit of Quintiles Transnational Corp. today announced an agreement to deploy a force of specialty sales representatives to provide support for hormone therapy Activella(R) (estradiol/norethindrone acetate tablets) and Vagifem(R) (estradiol vaginal tablets).

Under the terms of the agreement, Innovex will provide a dedicated team of 100 sales representatives in the U.S. for a two-year term. Innovex provides pharmaceutical companies with experienced representatives who have expertise in specific therapeutic areas to maximize opportunities for interaction with physicians.

"We are pleased to enter into this partnership with Innovex as one key factor in our ongoing efforts to ensure women have access to these important products," said Martin Soeters, president, Novo Nordisk. "Innovex's breadth of experience in working with women's health products positions the company as an ideal partner to support Novo Nordisk's commitment to growing the area of women's health in the United States."

Approved in the U.S. in November 1998, Activella is a continuous-combined once daily tablet for the treatment of moderate to severe vasomotor symptoms associated with menopause in women with an intact uterus. It is the only oral hormone therapy that combines 17beta-estradiol (an estrogen) and norethindrone acetate (a progestin), both of which are derived from plant sources. Activella is marketed in countries outside the U.S. by Novo Nordisk under the brand Activelle(R).

Vagifem, approved in the U.S. in March 1999, is a tablet containing natural estrogen, which is administered intravaginally by a disposable applicator for the treatment of atrophic vaginitis resulting from estrogen deficiency. As the first and only vaginal tablet, it offers a clean, no mess, convenient delivery, eliminating the messiness of other vaginal therapies such as creams. Vagifem has been marketed by Novo Nordisk in countries outside the U.S. since 1988.

As with all estrogen and progestin therapies, unopposed estrogen therapy has been associated with an increased risk of endometrial hyperplasia. The risk of developing uterine cancer depends on such factors as length, type of treatment and dosage strength. Concomitant use of a progestin can reduce this risk for women with an intact uterus. In clinical trials, the most commonly reported adverse events were breast pain, headache, postmenopausal bleeding and nausea for Activella(R) and headache, abdominal and back pain for Vagifem(R).

"We are especially proud to work with Novo Nordisk to promote these important women's health care products in the U.S. market," said Tony Yost, president, Innovex North America. "We have developed competency in this therapeutic area and every member of our sales team is committed to working with Novo Nordisk to establish the value of these products in this therapy area."

About Novo Nordisk

Novo Nordisk is a focused healthcare company. With the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems, Novo Nordisk is a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as hemostasis management, growth hormone therapy and hormone therapy for women. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 18,800 people in 68 countries and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For further company information visit http://www.novonordisk-us.com/ .

About Innovex

Innovex, a unit of Quintiles Transnational Corp., is a leading commercial solutions provider offering sales and marketing services designed to accelerate the success of pharmaceutical, biotech and other healthcare products. For more information visit http://www.innovex.com/.

Quintiles helps improve healthcare worldwide by providing a broad range of professional services, information and partnering solutions to the pharmaceutical, biotechnology and healthcare industries. Headquartered near Research Triangle Park, North Carolina, and with offices in more than 40 countries, Quintiles is a leading global pharmaceutical services organization and a member of the Fortune 1000. For more information visit the company's Web site at http://www.quintiles.com/ .

Information in this press release contains "forward looking statements" regarding Quintiles and Innovex that involve risks and uncertainties that could cause actual results to differ materially, including without limitation, the risk that the market for our products and services will not grow as we expect, our ability to efficiently distribute backlog among therapeutic business units and match demand to resources, actual operating performance, the ability to maintain large client contracts or to enter into new contracts, changes in trends in the pharmaceutical industry, and the ability to operate successfully in new lines of business. Additional factors that could cause actual results to differ materially are discussed in Quintiles' recent filings with the Securities and Exchange Commission, including but not limited to its Annual Report on Form 10-K, its Form 8-Ks, and its other periodic reports, including Form 10-Qs.

Novo Nordisk Pharmaceuticals, Inc.

CONTACT: Susan Jackson, +1-609-987-5800, stja@novonordisk.comChristian Kanstrup, Investor Relations, +1-609-987-5800, cka@novonordisk.com,both of Novo Nordisk Pharmaceuticals, Inc.; Tom Fuldner, Media Relations,+1-919-998-2052, tom.fuldner@quintiles.com, or Greg Connors, InvestorRelations, +1-919-998-2000, invest@quintiles.com, both of QuintilesTransnational Corp.


Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES